TG Therapeutics (TGTX) stock price, revenue, and financials

TG Therapeutics market cap is $3.2 b, and annual revenue was $152 k in FY 2019

$3.2 B

TGTX Mkt cap, 30-Oct-2020

$38 K

TG Therapeutics Revenue Q2, 2020
TG Therapeutics Net income (Q2, 2020)-52.9 M
TG Therapeutics EBIT (Q2, 2020)-50.8 M
TG Therapeutics Cash, 30-Jun-2020260.5 M
TG Therapeutics EV3 B

TG Therapeutics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.0k152.4k152.4k152.4k152.4k152.4k152.0k152.0k

Revenue growth, %

R&D expense

327.3k21.0m13.7m40.1m47.7m69.2m102.5m159.4m154.2m

General and administrative expense

554.7k4.8m16.3m15.2m15.0m

Operating expense total

882.0k25.8m13.7m40.1m47.7m69.2m118.9m174.6m169.2m

Depreciation and amortization

100.0k

EBIT

(882.0k)(26.9m)(23.0m)(55.7m)(63.2m)(79.0m)(118.7m)(174.4m)(169.1m)

EBIT margin, %

(141196%)(15071%)(36567%)(41462%)(51823%)(77905%)(114737%)(111220%)

Interest expense

7.1k905.7k952.9k930.7k972.7k5.3m

Interest income

30.8k55.0k174.7k323.0k

Investment income

15.8k

Pre tax profit

(25.9m)(118.5m)(173.5m)(172.9m)

Income tax expense

330.0k

Net Income

(853.1k)(18.1m)(20.5m)(55.8m)(62.9m)(78.3m)(118.5m)(173.5m)(172.9m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.1k38.0k38.0k38.0k38.0k38.0k38.0k38.0k38.0k

R&D expense

90.2k95.9k16.7m1.6m1.6m1.6m5.0m4.4m6.8m13.7m9.6m11.3m11.6m11.6m13.5m21.8m22.7m26.7m27.1m35.0m38.7m33.4m32.4m32.9m58.0m36.0m36.4m

General and administrative expense

232.7k165.9k644.0k1.5m1.2m2.2m1.6m3.2m5.1m3.8m5.0m5.9m2.3m2.4m2.5m3.2m5.0m1.8m4.5m6.6m5.7m968.0k2.3m2.7m2.9m14.3m14.4m

Operating expense total

322.9k261.8k17.4m3.1m2.7m3.8m6.7m7.6m12.0m17.5m14.6m17.1m13.9m14.0m16.1m25.0m27.7m28.5m31.6m41.6m44.4m34.4m34.7m35.6m60.9m50.3m50.9m

EBIT

(322.9k)(261.8k)(17.4m)(3.1m)(2.7m)(3.7m)(6.6m)(7.6m)(12.0m)(17.4m)(14.6m)(17.1m)(13.8m)(14.0m)(16.0m)(24.9m)(27.7m)(28.4m)(31.6m)(41.6m)(44.3m)(34.3m)(34.7m)35.5m(60.9m)(50.2m)(50.8m)

EBIT margin, %

(9749%)(17401%)(19964%)(31383%)(45777%)(38333%)(44918%)(36291%)(36730%)(42062%)(65428%)(72625%)(74617%)(82910%)(109413%)(116697%)(90337%)(91287%)93537%(160161%)(132224%)(133803%)

Interest expense

428.2k1.2m220.1k228.1k228.6k231.5k240.0k226.3k234.8k234.8k237.7k246.5k246.5k242.4k220.8k211.5k669.0k1.5m1.2m2.2m

Interest income

323.0196.01.1m

Investment income

(3.7k)4.1k5.0k1.5k1.2k

Pre tax profit

(3.7m)(6.6m)(7.5m)

Income tax expense

Net Income

(3.0m)(551.7k)(10.3m)(1.9m)(2.5m)(3.7m)(6.6m)(7.5m)(12.0m)(17.5m)(14.6m)(17.1m)(13.7m)(13.8m)(15.9m)(24.8m)(27.7m)(28.4m)(31.5m)(41.5m)(44.1m)(34.0m)(35.2m)36.2m(61.9m)(51.1m)(52.9m)

TG Therapeutics Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.7m16.5m40.5m55.7m55.1m25.0m56.7m42.0m112.6m

Accounts Receivable

83.9k

Prepaid Expenses

87.2k29.1k47.8k174.0k308.3k436.8k439.0k611.0k

Inventories

Current Assets

9.8m18.5m42.3m85.2m86.9m50.9m93.3m79.0m149.2m

PP&E

1.2k5.7k20.4k47.1k248.0k251.0k282.0k

Goodwill

629.8k799.4k799.4k799.4k799.4k799.4k799.4k799.0k799.0k

Total Assets

15.9m22.1m48.1m86.7m113.5m54.8m97.4m83.6m163.0m

Accounts Payable

4.0m9.3m15.3m25.9m36.4m30.0m

Short-term debt

877.8k677.8k677.8k275.2k211.5k68.9k127.6k67.0k

Current Liabilities

1.6m2.2m6.3m5.1m10.5m16.9m28.0m38.9m84.4m

Long-term debt

4.0m2.5m64.5k68.9k18.4m39.2m

Total Debt

4.9m3.2m677.8k275.2k423.1k137.8k255.2k134.0k39.2m

Total Liabilities

6.3m6.5m8.1m6.6m11.9m18.9m30.4m59.6m124.4m

Common Stock

284.7k25.8k34.3k45.0k54.1k73.2k84.0k109.0k

Preferred Stock

413.0

Additional Paid-in Capital

10.2m34.5m79.7m175.5m259.9m272.4m422.0m552.5m740.0m

Retained Earnings

(95.2m)(158.1m)236.4m(354.9m)(528.3m)(701.2m)

Total Equity

9.6m15.6m40.1m80.1m101.6m35.9m67.0m24.0m38.6m

Debt to Equity Ratio

0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x

Financial Leverage

1.7 x1.4 x1.2 x1.1 x1.1 x1.5 x1.5 x3.5 x4.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

492.5k212.3k20.9m20.4m17.4m15.2m13.4m50.2m49.6m37.1m53.2m86.0m60.3m65.5m36.5m28.6m29.2m95.6m77.6m91.8m82.9m105.7m70.7m64.3m57.2m44.7m52.1m260.5m

Prepaid Expenses

116.8k100.8k79.0k89.5k64.7k225.4k136.7k118.4k359.9k197.9k258.7k701.9k548.8k457.9k730.5k649.7k500.6k1.1m927.7k796.3k978.0k816.0k526.0k1.5m987.0k864.0k

Current Assets

609.3k313.0k21.0m20.5m19.2m17.8m14.2m50.6m56.3m49.3m76.7m115.7m103.7m104.7m70.6m69.6m71.3m119.0m97.0m97.7m117.0m136.0m109.7m105.1m94.4m80.4m88.0m280.9m

PP&E

1.8k1.6k1.4k1.3k1.0k2.5k3.8k8.2k7.3k7.8k24.8k34.8k69.2k323.0k333.9k327.7k307.7k289.3k268.4k252.0k265.0k268.0k241.0k237.0k275.0k320.0k331.0k

Goodwill

629.8k629.8k629.8k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.4k799.0k799.0k799.0k799.0k799.0k799.0k799.0k799.0k

Total Assets

18.4m18.1m27.1m26.5m25.2m21.4m17.9m54.3m58.2m56.3m77.5m117.3m123.6m127.4m100.1m94.8m75.7m123.3m101.2m101.8m121.0m140.7m114.4m117.5m106.6m93.3m101.8m294.6m

Accounts Payable

1.6m1.9m8.0m8.9m8.3m8.6m8.1m13.1m15.6m18.9m19.6m18.2m32.5m35.4m37.9m40.2m31.5m31.8m30.9m29.7m

Short-term debt

775.3k761.3k677.8k677.8k677.8k677.8k677.8k677.8k159.2k183.1k272.2k295.4k181.7k152.9k90.6k117.1k174.7k152.6k182.2k224.0k210.0k91.0k1.6m8.9m

Current Liabilities

3.8m1.5m1.2m2.3m3.0m2.5m3.5m5.7m2.0m2.6m8.9m9.6m9.2m9.7m8.9m14.1m16.9m19.7m20.8m19.8m33.3m36.9m40.2m60.9m56.0m80.2m63.1m67.5m

Long-term debt

16.5m16.4m4.7m4.4m4.4m2.4m2.4m2.3m115.6k36.5m36.6m38.1m39.4m32.2m

Total Debt

17.3m17.2m5.3m5.1m5.1m3.1m3.0m677.8k115.6k159.2k183.1k272.2k590.7k363.3k305.8k181.1k117.1k349.3k305.1k364.3k448.0k420.0k182.0k28.3m28.5m38.1m41.0m41.0m

Total Liabilities

20.5m18.4m5.9m6.7m7.3m6.7m7.6m9.7m3.7m4.2m10.5m11.0m10.7m11.1m10.6m16.1m18.9m22.2m23.2m22.2m35.8m39.3m42.6m98.3m93.4m119.1m103.2m100.4m

Common Stock

2.6k7.4k5.1k18.1k20.1k26.3k26.7k33.4k37.5k38.2k41.5k47.5k51.7k52.6k54.1k54.5k54.8k66.8k68.1k70.7k77.0k82.0k83.0k89.0k93.0k97.0k110.0k127.0k

Preferred Stock

1.1k

Additional Paid-in Capital

58.3m60.7m22.8m24.0m24.8m37.4m39.5m78.4m101.6m111.2m143.7m216.2m240.0m257.0m261.6m266.8m269.6m365.3m370.6m403.7m481.8m542.1m546.4m582.9m613.1m636.0m751.1m999.5m

Retained Earnings

(58.9m)(76.4m)(109.8m)(126.9m)(140.5m)(172.0m)(187.9m)(212.7m)(264.1m)(292.5m)(324.0m)(396.4m)(440.5m)(474.5m)(563.5m)599.7m(661.6m)(752.3m)(805.2m)

Total Equity

(2.1m)(294.6k)21.2m19.8m17.9m14.7m10.3m44.6m54.4m52.1m67.1m106.2m112.9m116.3m89.4m78.7m56.8m101.0m78.0m79.5m85.2m101.4m71.7m19.3m13.2m(25.8m)(1.4m)194.2m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x1.5 x2.2 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.2 x0.3 x

Financial Leverage

-8.5 x-61.3 x1.3 x1.3 x1.4 x1.5 x1.7 x1.2 x1.1 x1.1 x1.2 x1.1 x1.1 x1.1 x1.1 x1.2 x1.3 x1.2 x1.3 x1.3 x1.4 x1.4 x1.6 x6.1 x8.1 x-3.6 x-75.3 x1.5 x

TG Therapeutics Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(853.1k)(18.1m)(20.5m)(55.8m)(62.9m)(78.3m)(118.5m)(173.5m)(172.9m)

Depreciation and Amortization

235.01.1k3.9k15.5k63.0k82.4k88.0k100.0k

Accounts Payable

408.3k595.8k4.0m(603.4k)5.5m6.5m11.0m11.0m(4.8m)

Cash From Operating Activities

(86.6k)(5.2m)(10.8m)(35.1m)(44.7m)(61.6m)(93.8m)(128.9m)(132.8m)

Purchases of PP&E

(1.4k)(5.7k)(18.6k)(42.2k)(344.0k)(2.2k)(90.0k)(131.0k)

Cash From Investing Activities

10.4k(1.4k)(4.9m)(18.4m)(24.7m)26.5m(8.2m)1.2m(718.0k)

Short-term Borrowings

(200.0k)(677.8k)

Long-term Borrowings

Cash From Financing Activities

9.8m11.9m39.8m68.6m68.7m5.0m133.7m113.6m204.2m

Net Change in Cash

9.7m6.7m24.0m15.2m(652.5k)(30.0m)31.7m(14.1m)70.7m

Income Taxes Paid

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

849.8k298.1k(10.3m)(12.2m)(14.6m)(3.7m)(10.3m)(14.8m)(7.5m)(19.5m)(37.0m)(14.6m)(31.7m)(45.3m)(13.8m)(29.7m)(54.6m)(27.7m)(56.1m)(87.6m)(41.5m)(85.7m)(119.6m)(35.2m)71.4m(133.3m)(51.1m)(104.0m)

Depreciation and Amortization

1.2k1.4k118.0115.0309.0634.0706.01.6k2.5k2.4k5.8k10.3k6.4k23.3k42.5k20.4k41.1k62.0k20.0k41.0k64.0k23.0k46.0k72.0k30.0k64.0k

Accounts Payable

(15.9k)(55.8k)(254.6k)912.7k1.5m241.0k1.2m3.4m(3.9m)(3.0m)3.3m4.4m4.0m4.7m(1.6m)3.7m6.4m2.6m3.1m2.7m5.3m8.9m12.3m2.2m(5.6m)(3.8m)(1.6m)(728.0k)

Cash From Operating Activities

113.8k(166.4k)(861.6k)(1.4m)(4.4m)(2.2m)(4.8m)(5.9m)(8.3m)(11.9m)(20.0m)(8.9m)(21.1m)(31.8m)(16.7m)(29.5m)(44.6m)(22.3m)(49.1m)(71.9m)(28.0m)(62.2m)(95.2m)(33.4m)(69.2m)(102.4m)(62.1m)(105.9m)

Purchases of PP&E

(1.4k)(1.4k)(1.7k)(3.3k)(3.2k)(3.2k)(4.5k)(6.9k)(20.3k)(59.2k)(282.3k)(310.1k)(323.0k)(2.2k)(2.2k)(24.0k)(58.0k)(84.0k)(14.0k)(32.0k)(97.0k)(68.0k)(113.0k)

Cash From Investing Activities

(1.4k)(1.4k)(1.7k)(3.3k)(3.2k)(9.2m)(9.2m)3.8m(27.2m)(27.2m)(1.9m)(510.0k)15.1m6.0m11.0m19.8m1.8m7.4m942.0k(1.1m)(678.0k)(722.0k)1.5m12.7m

Short-term Borrowings

(100.0k)(100.0k)(200.0k)(200.0k)(200.0k)(677.8k)(677.8k)(677.8k)

Long-term Borrowings

Cash From Financing Activities

(100.0k)(100.0k)12.0m12.0m12.0m936.9k1.7m39.6m17.4m17.7m41.9m35.3m53.0m68.7m14.2k3.6m3.6m86.9m90.7m118.9m52.4m104.5m108.9m56.9m85.2m105.9m81.0k241.2m

Net Change in Cash

13.8k(266.4k)11.2m10.6m7.6m(1.3m)(3.0m)33.7m9.1m(3.4m)12.7m30.3m4.6m9.7m(18.6m)(26.5m)(25.9m)70.6m52.6m66.8m26.2m49.6m14.7m22.4m15.3m2.7m(60.6m)147.9m

Interest Paid

363.0882.0777.0k1.6m

TG Therapeutics Ratios

USDQ2, 2011

Financial Leverage

-8.5 x